Title |
Synthesis and antiproliferative activities of quebecol and its analogs
|
---|---|
Published in |
Bioorganic & Medicinal Chemistry Letters, August 2013
|
DOI | 10.1016/j.bmcl.2013.07.058 |
Pubmed ID | |
Authors |
Kasiviswanadharaju Pericherla, Amir Nasrolahi Shirazi, V. Kameshwara Rao, Rakesh K. Tiwari, Nicholas DaSilva, Kellen T. McCaffrey, Yousef A. Beni, Antonio González-Sarrías, Navindra P. Seeram, Keykavous Parang, Anil Kumar |
Abstract |
Simple and efficient synthesis of quebecol and a number of its analogs was accomplished in five steps. The synthesized compounds were evaluated for antiproliferative activities against human cervix adenocarcinoma (HeLa), human ovarian carcinoma (SK-OV-3), human colon carcinoma (HT-29), and human breast adenocarcinoma (MCF-7) cancer cell lines. Among all the compounds, 7c, 7d, 7f, and 8f exhibited antiproliferative activities against four tested cell lines with inhibition over 80% at 75 μM after 72 h, whereas, compound 7b and 7g were more selective towards MCF-7 cell line. The IC50 values for compounds 7c, 7d, and 7f were 85.1 μM, 78.7 μM, and 80.6 μM against MCF-7 cell line, respectively, showing slightly higher antiproliferative activtiy than the synthesized and isolated quebecol with an IC50 value of 104.2 μM against MCF-7. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 33 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 18% |
Researcher | 6 | 18% |
Student > Bachelor | 3 | 9% |
Student > Master | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Other | 6 | 18% |
Unknown | 7 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 10 | 30% |
Agricultural and Biological Sciences | 3 | 9% |
Environmental Science | 2 | 6% |
Nursing and Health Professions | 2 | 6% |
Engineering | 2 | 6% |
Other | 4 | 12% |
Unknown | 10 | 30% |